FDA Commissioner Launches Controversial Expert Panels with Financial Conflicts, Raising Transparency Concerns

FDA Commissioner Marty Makary has launched a series of ad hoc "expert panels" to discuss controversial pharmaceutical topics, raising concerns among former agency officials about potential violations of federal transparency and conflict-of-interest rules. The panels, which have addressed antidepressants, menopause drugs, and talc safety, feature physicians and researchers who often hold contrarian views and have financial interests in the subjects under discussion.

Departure from Traditional Advisory Structure

The FDA traditionally relies on more than 30 established advisory panels composed of carefully vetted experts specializing in various drugs, vaccines, and medical products. These official panels operate under strict government transparency rules regarding scheduling, composition, and disclosure of financial conflicts, with required public comment periods and detailed FDA scientific memos.

Makary's informal panels have not included these standard elements, prompting criticism from former agency officials. "These meetings are a chance to advance RFK's pet peeves — talc, antidepressants, fluoride — with people who have been handpicked," said Dr. Peter Lurie, a former FDA official who now serves as president of the Center for Science in the Public Interest. "Nobody would put forward these panels as representing the general scientific opinion on these topics."

Controversial Panel Compositions

Antidepressant Safety Panel

The July meeting on antidepressant safety during pregnancy featured doctors who have testified in class action lawsuits, alongside experts who allege the drugs cause autism, birth defects, and other conditions — links that are not supported by established science. The session cataloged unsubstantiated theories about the medications, often based on animal studies.

Several participants had served as expert witnesses against drugmakers, including in lawsuits alleging that antidepressants cause homicidal behavior. All but one of the panelists have criticized the drugs in books, articles, interviews, or other forums. "It's never been possible to identify a group of people who do particularly well on antidepressants," said Dr. Joanna Moncrieff, a British psychiatrist and co-founder of a group critical of mainstream psychiatric medicine.

The meeting concluded with all but one expert calling for a new boxed warning — the most serious type — about antidepressant risks for mothers and developing babies. The American College of Obstetricians and Gynecologists called the panel "alarmingly unbalanced" and full of "outlandish and unfounded claims."

Menopause Hormone Therapy Panel

The menopause meeting took an opposite approach, with experts urging removal of long-standing warnings on estrogen-based drugs. Most physicians at that meeting prescribe the hormones or are involved with pharmaceutical industry campaigns opposing the warning labels.

The panel's views aligned with Makary's position that current warning labels overstate hormone therapy risks. "Hormone replacement therapy for women is basically a modern-day miracle," Makary told a podcast host last year. However, FDA guidance specifically advises against using these drugs to prevent chronic conditions due to lack of clear benefit, with approval limited to specific menopause symptoms like hot flashes.

Nearly 80 researchers sent a letter to the FDA objecting to the "two-hour meeting of hormone proponents" and calling for an official advisory committee meeting.

Regulatory and Legal Implications

Former FDA lawyers warn that the agency could face legal challenges if it attempts to use Makary's informal panels as the basis for regulatory decisions. Genevieve Kanter, a health policy specialist at the University of Southern California, suggests the meetings appear "more designed as a forum to put a stamp of approval on predetermined opinions."

"The information in these panels could be used in litigation and presented as coming from experts or representing some intellectual consensus that doesn't exist," Kanter noted.

Scientific Community Response

The panels have drawn criticism for promoting views that contradict established medical consensus. Regarding antidepressants during pregnancy, psychiatric experts emphasize that the well-documented risks of untreated maternal depression — including pregnancy complications, substance abuse, and suicide — far outweigh the medications' known risks of excess bleeding and lower birth weight in newborns.

"I tell people I'm working with that the best thing they can do for themselves and their baby is to get the treatment that they need," said Dr. Nancy Byatt of University of Massachusetts' Chan Medical School.

Ongoing Debate Over Hormone Therapy

The hormone therapy discussions reflect ongoing debate about a landmark study of more than 26,000 postmenopausal women that was halted over 20 years ago when scientists discovered serious health risks outweighed benefits. All estrogen drugs still carry boxed warnings about higher rates of stroke, blood clots, and cognitive problems.

Some doctors argue these warnings are exaggerated and should be removed from certain products, such as low-dose creams for vaginal dryness. Makary has raised the possibility of removing warnings from higher-dose pills, patches, and sprays as well.

Transparency Concerns

The FDA has not disclosed how panelists were selected for these meetings. Critics argue that genuine transparency would require balanced panels of experts carefully screened for conflicts, with public participation opportunities.

"If you really wanted to be transparent about these issues you'd put together a balanced panel of experts, who have been carefully screened for conflicts and you'd invite the public in," Lurie said. "But that's the antithesis of what's going on in these cases."

A spokesperson for Kennedy did not answer specific questions about the panels but stated they represent an effort to "apply rigorous, evidence-based standards to ingredient safety and modernize regulatory oversight." It remains unclear whether the FDA will implement changes based on these panel recommendations or respond to calls for official advisory committee meetings.